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Abstract
Introduction Recent studies have demonstrated that members 
of the GATA-binding protein (GATA) family (GATA4 and 
GATA5) might have pivotal roles in the transcriptional 
upregulation of mucin genes (MUC2, MUC3 and MUC4) in 
gastrointestinal epithelium. The zinc-finger GATA3 transcription 
factor has been reported to be involved in the growth control 
and differentiation of breast epithelial cells. In SAGE (serial 
analysis of gene expression) studies we observed an intriguing 
significant correlation between GATA3 and MUC1 mRNA 
expression in breast carcinomas. We therefore designed the 
present study to elucidate whether MUC1 expression is 
regulated by GATA3 in breast cancer cells.
Methods Promoter sequence analysis of the MUC1 gene 
identified six GATA cis consensus elements in the 5' flanking 
region (GATA1, GATA3 and four GATA-like sequences). 
Chromatin immunoprecipitation and electrophoretic mobility­
shift assays were employed to study the presence of a functional 
GATA3-binding site. GATA3 and MUC1 expression was 
analyzed in vitro with a GATA3 knockdown assay. Furthermore, 
expression of GATA3 and MUC1 genes was analyzed by real­
time RT-PCR and immunohistochemistry on breast cancer­
specific tissue microarrays.
Results We confirmed the presence of a functional GATA3- 
binding site on the MUC1 promoter region in the MCF7 cell line. 
We determined that GATA3 knockdown assays led to a 
decrease in MUC1 protein expression in MCF7 and T47D cells. 
In addition, we detected a statistically significant correlation in 
expression between GATA3 and MUC1 genes at the mRNA 
and protein levels both in normal breast epithelium and in breast 
carcinomas (p = 0.01). GATA3 expression was also highly 
associated with estrogen receptor and progesterone receptor 
status (p = 0.0001) and tumor grade (p = 0.004) in breast 
carcinomas.
Conclusion Our study provides evidence indicating that 
GATA3 is probably a mediator for the transcriptional 
upregulation of MUC1 expression in some breast cancers.
Introduction
GATA3 (GATA-binding protein 3) belongs to a family of tran­
scription factors (GATA1 to GATA6) that bind with high affin­
ity to the consensus sequence (A/T)GATA(A/G) and share a 
steroid-hormone-receptor superfamily C4 zinc-finger DNA- 
binding motif [1]. GATA factors are classified into two sub­
families on the basis of structural features and expression pat­
terns. The expression of GATA1, GATA2, and GATA3 has 
been detected predominantly in hematopoietic cells, whereas 
GATA4, GATA5, and GATA6are expressed mainly in the car­
diovascular system and in endodermal-derived tissues includ­
ing liver, lung, pancreas, and intestine [2]. The function of 
GATA factors is modulated by their interaction with other tran­
bp = base pairs; ChIP = chromatin immunoprecipitation; DAB = diaminobenzidine; DTT = dithiothreitol; ELISA = enzyme-linked immunosorbent 
assay; EMSA = electrophoretic mobility-shift assay; ER = estrogen receptor; ESR1 = gene encoding estrogen receptor a; GATA3 = GATA-binding 
protein 3; HRP = horseradish peroxidase; IDC= invasive ductal carcinoma; MUC1 = mucin 1; PR = progesterone receptor; RT-PCR = reverse-tran- 
scriptase-mediated polymerase chain reaction; SAGE = serial analysis of gene expression; TMA = tissue microarray.
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scription factors, transcriptional coactivators and co-repres- 
sors.
In genome-wide expression profile studies from our laboratory 
we observed that the expression of GATA3 is highly corre­
lated with estrogen receptor-a (ERa) status in breast carcino­
mas [3] similar results were reported by others [4-9]. Parikh 
and colleagues (2005) suggested that GATA3 expression 
might be associated with responsiveness to hormone therapy 
in breast cancer patients [10]. Furthermore, the expression of 
GATA3 has been shown to correlate with specific breast can­
cer phenotypes, defined as luminal type A, carrying an 
improved disease-free survival and overall survival when com­
pared with tumors that do not express GATA3 [11]. It has 
been reported that GATA3 may be involved in growth control 
and differentiation in breast epithelial cells mediating the tran­
scriptional activation of several genes such as those encoding 
cytokeratins 5, 6 and 17, and trefoil factors 1 and 3 [12]. 
Recent evidence indicates that the proteins GATA4, GATA5, 
and GATA6 may be important in the upregulation of mucin 
expression (MUC2, MUC3, and MUC4) and trefoil factor 
genes (TFF1 and TFF2j, events that are in turn associated 
with gastrointestinal epithelial cell differentiation [13-15].
The MUC1 glycoprotein is a member of the mucin family of 
proteins, expressed mostly on the apical membrane of various 
glandular epithelia such as in luminal breast epithelial cells 
[16]. The association of MUC1 overexpression with loss of 
cell polarity has been observed in breast carcinomas. Abnor­
mal MUC1 expression leads to a loss of cell-cell and cell- 
extracellular-matrix adhesion [17]. It was further determined 
that this increase in MUC1 expression is due mainly to tran­
scriptional regulatory events [18].
The 5'-regulatory region of the human MUC1 gene was ana­
lyzed previously [19-21]. Several consensus binding sites for 
transcription factors were observed in this promoter region, 
such as those for the SP1, STAT 1, STAT3, NF-kB, MZF1 and 
DbpA proteins, all of which may be involved in the transcrip­
tional regulation of MUC1 [18,20,22]. However, the factors 
determining MUC1 tissue-specific expression remain largely 
unknown, as do the mechanisms causing MUC1 overexpres­
sion in tumors.
Global gene expression studies pointed to a significant corre­
lation in the overexpression of GATA3 and MUC1 genes com­
monly observed in breast cancer. Interestingly, we also 
observed the presence of multiple putative GATA-binding 
sites throughout the MUC1 promoter. Thus, the aim of this 
study was to evaluate the role of GATA3 as a putative tran­
scriptional regulator of MUC1 in breast cancer.
Materials and methods
Serial analysis of gene expression database mining
To perform a comparative analysis of the GATA family mem­
bers expressed in breast tissue, we analyzed 47 breast SAGE 
(serial analysis of gene expression) libraries: 4 normal breast 
epithelium, 8 ductal carcinoma in situ (DCIS), 33 invasive duc­
tal carcinomas (IDCs), and the MCF7 and ZR75 breast cancer 
cell lines. To this end, we combined 29 breast cancer SAGE 
libraries generated by us at a resolution of 100,000 tags per 
library (Aldaz Laboratory) with 18 SAGE libraries (generated 
at the Polyak Laboratory, Dana-Farber Cancer Institute, Bos­
ton, MA, USA) downloaded from the Cancer Genome Anat­
omy Project - SAGE Genie database [23]. SAGE data 
management and tag-to-gene matching for GATA1 (GCCTC- 
CAGAG), GATA2 (GACAGTTGTT), GATA3 (AAGGAT- 
GCCA), GATA4 (TCTCTCCCCT), GATA5 
(TCCTGGCATA), GATA6 (GAGAAGATCA), ESR1 
(AGCAGGTGCC), and MUC1 (CCTGGGAAGT) were per­
formed with a suite of web-based SAGE library annotation 
tools developed by us [24]. To enable the visualization and 
illustration of our analyses, we used the TIGR MultiExperiment 
Viewer (MeV 2.2) software (The Institute for Genomic 
Research, Rockville, MD, USA). This tool was employed for 
normalization and average clustering of the SAGE data. 
Spearman's test was employed for a correlation analysis of 
transcripts. The CGAP-dbEST and Oncomine databases [25] 
were employed for collection and visualization of gene expres­
sion profiles of the previously mentioned transcripts from pub­
licly available breast cancer ESTs and microarray data sets 
(Additional file 1).
Real-time RT-PCR expression analysis in breast 
carcinomas
For validation studies, total RNA was isolated from an inde­
pendent set of 36 snap-frozen breast carcinomas (stages I 
and II: 13 ERa-negative tumors and 23 ERa-positive tumors) 
using TRIzol reagent (Invitrogen, San Francisco, CA, USA). 
Template cDNAs were synthesized with the SuperScript™ 
First-strand Synthesis System (Invitrogen). GATA3 and 
MUC1 primers and probes were obtained from Applied Bio­
systems (TaqMan Assays-on-Demand™ Gene Expression 
Products; Foster City, CA, USA). All the PCR reactions were 
performed with the TaqMan PCR Core Reagents kit and the 
ABI Prism® 7700 Sequence Detection System (Applied Bio­
systems). Experiments were performed in duplicate for each 
data point and 18S rRNA was used as control. Results are 
expressed as means ± 2 SEM based on log2 transformation of 
normalized real-time RT-PCR values of the assayed genes.
Tissue microarray and immunostaining analysis
We used breast-specific tissue microarrays (TMAs) from two 
sources (Fox Chase Cancer Center, Philadelphia, and Coop­
erative Breast Cancer Tissue Resource, NCI-CBCTR) for 
GATA3 and MUC1 protein expression profiling. We analyzed 
a total of 263 cases (38 normal tissues (19 DCIS and 206 
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IDCs). Information on ER and progesterone receptor (PR) sta­
tus was available for all IDC cases. Before immunostaining, 
endogenous peroxidase activity was blocked with 3°/o H2O2 in 
water for 10 minutes. Heat-induced epitope retrieve was per­
formed with 1.0 mM EDTA buffer pH 8.0 for 10 minutes in a 
microwave oven followed by cooling for 20 minutes. To block 
non-specific antibody binding, the slides were incubated with 
10% goat serum in PBS for 30 minutes. Primary monoclonal 
anti-GATA3 (HG3-31: SC-268; Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) and anti-MUC1 (VU4H5: SC-7313; 
Santa Cruz Biotechnology) antibodies were used at 1:50 and 
1:100 dilutions respectively. Antibody detection was per­
formed using diaminobenzidine (DAB). Staining intensity was 
determined by means of a Chromavision Automated Cellular 
Imaging System (ACIS®) with the generic DAB software appli­
cation, as described previously [26]. This software determines 
brown intensity regardless of the area covered by the positive 
cells.
Multivariate analysis was performed by principal components 
analysis (PCA). Variables were codified and transformed as 
follows: negative staining (0) and positive staining (1) for ER, 
PR, GATA3 and MUC1 expression; normal tissue (0), DCIS 
(1) and IDC (2) for histology; lymph node-negative (0) and 
lymph node-positive (1) status; and low (1), moderate (2) and 
high (3) tumor grade. To enable visualization of the factorial 
analysis, we employed a three-dimensional representation of 
component plot in rotated space. The basic significance level 
was fixed at p < 0.05 and all data were analyzed with SPSS® 
statistical software (SPSS Inc., Chicago, IL, USA).
Cell culture, western blot and immunocytochemistry 
analyses
The estrogen-dependent breast cancer cell lines MCF7 and 
T47D were grown in RPMI-1640 medium (Gibco, Gaithers­
burg, MD, USA) supplemented with 10% (v/v) FBS (Bioser, 
Buenos Aires, Argentina), 10 U/ml penicillin G, and 10 pg/ml 
streptomycin.
Trypan blue staining was used to assess cell viability. Cells (3 
x 106) were lysed with 1 ml of RIPA buffer (50 mM Tris pH 7.5, 
150 mM NaCI, 0.5% sodium deoxycholate, 1% Triton X-100, 
0.1% SDS) containing protease inhibitor. For western blotting, 
50 pl of cell extract was separated by 10% SDS-PAGE and 
transferred to nitrocellulose membrane (Protran®; BioScience, 
Dassel, Germany). Immunodetection was performed with a 
GATA3 mouse monoclonal antibody (HG3-31) at 1:300 dilu­
tion, followed by incubation with horseradish peroxidase 
(HRP)-conjugated secondary antibody (anti-mouse-HRP; 
Sigma, St Louis, MO, USA) at 1:1000 dilution. Immunostain­
ing was performed with DAB as substrate.
MCF7 cells were also grown on coverslips; these preparations 
were washed twice with 1 x PBS and fixed with 10% formal­
dehyde in 1 x PBS. Immunodetection of GATA3 was 
assessed with HG3-31 monoclonal antibody. Primary antibod­
ies were detected with biotin-conjugated goat anti-mouse 
IgG, followed by incubation with streptavidin-conjugated HRP 
and using DAB as a substrate. The cells grown on coverslips 
were counterstained with hematoxylin and examined by light 
microscopy.
MUC1 promoter sequence analysis and chromatin 
immunoprecipitation
The complete sequence of the human MUC1 promoter region 
was obtained from GenBank (accession no. NM 002456). 
We used the DNAMAN software (Version 4.15; Lynnon Bio- 
Soft, Vaudreuil-Dorion, Quebec, Canada) to identify putative 
GATA-binding sites (A/T-GATA-A/G) in this regulatory 
sequence.
MCF7 breast cancer cells were grown to 90% confluence; 
culture medium was then removed. Cells were washed and 
fixed with 1 % formaldehyde in 1 x PBS for 10 minutes at room 
temperature. Fixed cells were washed twice with 1 x PBS, 
scraped off and incubated in 1 ml of lysis buffer A (20 mM 
HEPES pH 7.9, 25% glycerol, 420 mM NaCI, 1.5 mM MgCI2, 
0.2 mM EDTA, 1 mM phenylmethylsulphonyl fluoride), fol­
lowed by a second incubation in 300 pl of lysis buffer B (50 
mM Tris-HCI pH 8.0, 1 mM EDTA, 150 mM NaCI, 1% SDS, 
2% Triton X-100). The cell lysate was then sonicated with a 
Branson Sonifier 450 (30-second pulses at 40% output) and 
subjected to immunoprecipitation with mouse monoclonal 
antibody HG3-31 against GATA3, at 4°Cfor 1 hour; 50 pl of 
Protein A-Sepharose (1:1 slurry) was added to the reaction 
and incubated at 4°C for 4 hours. The unbound proteins were 
removed by washing the Protein A-Sepharose with Triton 
buffer (50 mM Tris-HCI pH 8.0, 1 mM EDTA, 150 mM NaCI, 
0.1% Triton X-100) and 1 x PBS. The antigen-antibody com­
plex was eluted with SDS-NaCI-dithiothreitol (DTT) buffer 
(62.5 mM Tris-HCI pH 6.8, 200 mM NaCI, 2% SDS, 10 mM 
DTT). The eluted protein-DNA complex was incubated over­
night at 68°C. DNA was isolated with the phenol/chloroform 
extraction and ethanol precipitation protocol.
The PCR reactions were performed with 15 ng of DNA, 2.5 
mM MgCI2, each dNTP at 200 pM, 25 pmol of muc1p1 for­
ward primer (5'-tagaagggtggggctattcc-3'), 25 pmol of 
muc1p1 reverse primer (5'-taggtcgaggtcctgtacag-3', flanking 
the GATA1-binding site), 25 pmol of muc1p2 forward primer 
(5'-tttggctgatttggggatgc-3'), 25 pmol of muc1p2 reverse 
primer (5'-aatattgcactcgtcccgtc-3', flanking the GATA3-bind- 
ing site), and 1.25 units of Taq DNA polymerase (Promega, 
Madison, Wl, USA), in PCR buffer (20 mM Tris-HCI pH 8.4, 
50 mM KOI) in a final volume of 50 pl. The reactions were 
cycled as follows: 1 cycle of 94°C for 2 minutes and 25 cycles 
of 94°C for 1 minute, 56°C for 1 minute, and 72°C for 1 
minute. HLA-DQa 1 amplicon (242 bp) was used as control 
(exon sequence without a GATA-binding site) [27]. Separa­
tion and detection of the amplified fragments were performed 
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by electrophoresis on a 6°/o minigel (19:1 polyacryla- 
mide:bisacrylamide) and staining with silver.
Electrophoretic mobility-shift assay
Nuclear protein extract from the MCF7 cell line was prepared 
as described [28]. The following double-stranded DNA 
probes (27 bp) were used: the wild-type GATA consensus oli­
gonucleotide (5'-cacttgataacagaaagtgataactct-3') as positive 
control [4]; the MUC1 promoter sequence encoding the puta­
tive GATA3-binding site (5'-ggcggatctttgatagactggagtgtc-3'); 
and a double GATA3-binding site mutated variant (with transi­
tions G—>C and A—>T: 5'-ggcggatctttcttagactggagtgtc-3'). A 
non-isotopic electrophoretic mobility-shift assay (EMSA) was 
performed with 5 pg of nuclear cell extracts and 50 ng of the 
probe, 1 pg of salmon testes DNA (Sigma-Aldrich, St Louis, 
MO, USA) in a 5 x binding reaction buffer (100 mM Hepes pH 
7.9, 250 mM KCI, 2.5 mM DTT, 0.25 mM EDTA, 5 mM MgCI2, 
25% glycerol). After 20 minutes the samples were separated 
on a 10% polyacrylamide (39:1 polyacrylamide:bisacrylamide) 
at a constant temperature of 4°C with 1 x Tris-borate-EDTA 
(45 mA for 4.5 hours). Gels were stained with a previously 
described silver staining technique [27]. Similarly, for the 
supershift assay, 1 pg of specific antibody (anti-GATA3) or 
control antibody (anti-ERp) was incubated for 20 minutes in 
the MCF7 nuclear protein extract before the addition of 
probes. Samples were size separated by electrophoresis in a 
10% polyacrylamide minigel (39:1 polyacrylamide:bisacryla- 
mide) at room temperature with 0.5 x Tris-borate-EDTA.
GATA3 anti-sense phosphorothioate oligonucleotide 
assay
Anti-sense oligodeoxynucleotides were synthesized that 
matched the translational start region of GATA3 (5'-cgccgt- 
cacctccatggcctc-3') [29]. The GATA3 anti-sense oligodeoxy­
nucleotide used was synthesized on a phosphorothioate 
backbone to improve resistance to endonucleases (IDT, Cor­
alville, IA, USA). MCF7 and T47D cells were plated on 50 mm 
cultured dishes at 50% confluence in Opti-MEM® I Reduced 
Serum Medium (Invitrogen) and transiently transfected with 3 
pg of GATA3 anti-sense mixed with Lipofectamine in accord­
ance with the manufacturer's protocol (Invitrogen). Cells were 
maintained at 37°C and harvested at two time points after 
transfection (48 and 72 hours). Cells were lysed in RIPA 
buffer, and total protein concentration was estimated by 
Lowry's method. Equal amounts of protein were used for the 
western blot analyses. GATA3 and MUC1 immunodetection 
were assessed with HG3-31 and CT2 (epitope correspond­
ing to the carboxy terminus of MUC1) monoclonal antibodies, 
respectively. Primary antibodies were detected with biotin- 
conjugated goat anti-mouse IgG (for HG3-31) or biotin-SP- 
conjugated goat anti-Armenian hamster IgG (for CT2) (Jack- 
son ImmunoResearch), followed by incubation with streptavi- 
din-conjugated HRP and using DAB as a substrate. SDS- 
PAGE with silver staining was employed for the detection of 
total protein loaded.
In addition, we analyzed the expression of MUC1 protein and 
its response to GATA3 anti-sense by an ELISA assay with 
MCF7 cell culture. In brief, MCF7 cells were cultured on a 96- 
well microtitre plate and treated with 0.05 pg of GATA3 anti­
sense (48 hours), and then blocked with 1% BSA. MUC1 
immunodetection was performed with HMFG1 monoclonal 
antibody. The bound primary antibody was detected with per- 
oxidase-conjugated goat anti-mouse IgG. Color was devel­
oped with ABTS (2,2'-Azinobis (3-ethylbenzthiazoline-6- 
sulfonic acid)) substrate solution and absorbance was meas­
ured at 405 nm with a microplate reader (SLT Spectra, SLT 
Labinstruments, Salzburg, Austria). MUC1 expression was 
expressed as mean optical density with a 95% confidence 
interval. Statistically significant difference was estimated by t 
test (p < 0.05).
Results
GATA transcription factors family members expressed in 
breast epithelial cells
Interestingly, among the GATA family members GATA3 was 
by far the most frequently expressed GATA transcription fac­
tor in breast cancer. Specifically, GATA3 was detected as 
being expressed in 90% of the breast cancer cases (42 out of 
47) according to SAGE database analyses. In contrast, GATA 
family members GATA1, GATA2, GATA4, GATA5, and 
GATA6 were detected as expressed in only 13% (6 out of 47) 
of the SAGE libraries (Figure 1). Similarly, expressed 
sequence tag database and DNA microarray analyses showed 
that the GATA3 gene is expressed mainly in breast carcino­
mas compared with other GATA genes (Additional file 1). The 
MCF7 breast cancer cell line displayed the highest GATA3 
expression level observed. We detected a significant positive 
correlation between ESR1 (the gene encoding ERa) and 
GATA3 tags (r = 0.702; p = 0.0001), between ESR1 and 
MUC1 (r = 0.46; p = 0.001), and between GATA3 and 
MUC1 (r= 0.45; p = 0.002) (Figure 1).
GAT A3 and MUC1 real-time RT-PCR analysis in breast 
carcinomas
To validate the relationship of GATA3 and MUC1 in breast 
cancer epithelial cell further, we performed an mRNA expres­
sion analysis of 36 primary breast carcinomas by means of 
real-time RT-PCR. These data showed a significant positive 
correlation between the mRNA levels of both markers (r= 0.6; 
p < 0.0001) (Figure 2a). Furthermore, mRNA expression of 
GATA3 and MUC1 correlated positively with breast carcino­
mas ERa status (r = 0.492, p = 0.004; r= 0.608, p = 0.001, 
respectively) (Figure 2b,c).
GATA3 and MUC1 tissue-microarray analysis
PCA of 263 breast tissue samples (Figure 3a; Additional file 
2) identified statistically significant positive correlations 
between GATA3 expression and ER/PR status (Tb= 0.53; p = 
0.001) (Figure 3a,b). It is interesting to note that GATA3 and 
MUC1 protein expression are positively correlated among nor-
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Figure 1
Digital northern analysis based on SAGE data of GATA family members, ESR1 and MUC1 genes in 47 breast SAGE libraries. The color scale at the 
bottom represents expression level based on numbers of transcripts (tags) per library. SAGE, serial analysis of gene expression.
mal breast samples as well as in breast carcinomas (Tb= 0.44; 
p = 0.01). Additionally, MUC1 expression was correlated with 
lymph node-positive status in breast carcinomas Ctb = 0.46; p 
= 0.006). We detected a strong correlation between the lack 
of GATA3 expression and higher histological tumor grade 
(poorly differentiated) demonstrated by multivariate (Tb = - 
0.49; p = 0.002) and univariate (p = 0.004) analyses (Figure 
3a,c). Whereas 54.3% (19 out of 35) of IDC grade I and 45% 
(40 out of 89) of IDC grade II tumors were GATA3-positive, 
only 27% (18 out of 67) of IDC grade III tumors were GATA3- 
positive (p = 0.013).
Overall, these studies showed a consistently statistically sig­
nificant correlation between GATA3 and MUC1 expression at 
the mRNA and protein levels by SAGE profiling (p = 0.002), 
real-time RT-PCR (p < 0.0001), and TMA (p = 0.01) in breast 
carcinomas.
Identification of GATA c/s-elements within MUC1 
promoter
Analysis of the MUC1 promoter sequence indicated the pres­
ence of six putative GATA binding sites at -446/-451 
(GATA1), -1444/-1449 (GATA-like), -1572/-1577 (GATA- 
like), -2398/-2393 (GATA3), -2475/-2470 (GATA-like), and - 
2602/-2607 (GATA-like) (Figure 4). These sites encode the 
conserved consensus sequence required for the binding of 
GATA factors. To determine whether GATA3 is capable of 
binding the -2398/-2393 sequence in vivo, we performed a 
chromatin immunoprecipitation (ChIP) assay with nuclear 
extracts obtained from the MCF7 breast cancer cell line. In 
brief, protein-DNA complexes were crosslinked in vivo, soni­
cated and then immunoprecipitated with anti-GATA3 mono­
clonal antibodies. DNA samples were obtained from three 
fractions: input, non-specific eluted, and immunoprecipitated. 
These DNA samples were subjected to PCR with two sets of 
primers that flanked the predicted GATA3-binding site (- 
2398/-2393) and the putative GATA1-binding site (-446/- 
451) in the MUC1 promoter region.
In addition, we employed a set of primers spanning the second 
exon of the HLA-DQA1 gene (242 bp), used as negative con­
trol because there are no GATA-binding motifs in its 
sequence. The amplified product corresponding to the 
GATA1-binding site (186 bp) was detected from input DNA 
and non-specific GATA3-eluted DNA fractions (Figure 5a). 
However, this GATA1-related amplified product was not 
detected from the anti-GATA3-immunoprecipitated DNA frac­
tion (Figure 5a), indicating that the GATA3 protein does not 
recognize the -446/-451 site from the MUC1 promoter region.
Figure 2
GATA3 and MUC1 real-time RT-PCR analysis in 36 invasive breast carcinomas, (a) Linear regression analysis of GATA3 and MUC1 mRNA expres­
sion levels in invasive ductal carcinoma (IDC) with 95°/o mean prediction interval (r= 0.6; p < 0.0001). (b,c) GATA3 (p = 0.008) (b) and MUC1 (p 
= 0.009) (c) mRNA expression of IDC in association with ERa status. Results are real-time RT-PCR values of the assayed gene relative to 18S 
rRNA used as normalizing control and are shown as means ± 2 SEM based on a log2 transformation.
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Figure 3
GAT A3
Histotogy
♦ Grade
p°nent i
Tissue microarray analysis of 263 breast normal and cancer tissue sam­
ples. (a) Component plot in rotated space showing factors positively 
correlated, namely estrogen receptor/progesterone receptor (ER/PR; p 
= 0.0001), ER-PR/GATA3 (p =0.001), and MUC1 /lymph node status 
(p = 0.006), GATA3/MUC1 (p = 0.01); and factors negatively corre­
lated, namely ER-PR/tumor grade (p = 0.0001) and GATA3/tumor 
grade (p = 0.002). (b,c) Univariate analysis showing highly statistical 
association between GATA3 immunostaining and ER and PR status (p 
= 0.0001) (b) and statistical decrease trend in GATA3 immunostaining 
and the tumor grade of invasive component (p = 0.004) (c). Results are 
based on the brown intensity of immunostaining as described in the 
Materials and methods section, and are shown as means ± 2 SEM.
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Identical results were obtained for the HLA-DQA/-amplified 
products (negative control), demonstrating the specificity of 
the ChIP assay (Figure 5b). In contrast, the amplified product 
spanning the GATA3-binding site (292 bp in size) was 
detected in the input and anti-GATA3-immunoprecipitated 
DNA fractions (Figure 5c). These amplified products were 
detected only in the second immunoprecipitated DNA fraction 
(reChIP assay; Figure 5e). Furthermore, we employed an 
EMSA approach to validate the ChIP findings. Nuclear extract 
retarded the mobility of the GATA3 sequence-specific probe 
(positive control) and the probe encoding the putative GATA3- 
binding site (5'-ggcggatctttgatagactggagtgtc-3') found in the 
wild-type MUC1 promoter region (-2398/-2393) (Figure 6). In 
contrast, electromobility was not affected when a point mutant 
of the aforementioned MUC1 probe (T/CTTA/G instead of the 
wild-type T/GATA/G) was employed, indicating that no pro­
tein binding occurred (Figure 6). The presence of GATA3 in 
the retarded probe-protein complex was confirmed by super­
shift analysis (Figure 6b). The addition of anti-GATA3 antibody 
to the binding reaction showed a further decrease in the mobil­
ity of the probe-protein complex. Addition of the control anti­
body (anti-ERp) had no effect.
Overall, these data indicate that endogenous GATA3 protein 
molecules from the MCF7 breast cancer cell line were able to 
associate with the putative GATA3-binding site of MUC1 pro­
moter sequence, as demonstrated with in vivo and in vitro 
assays.
GATA3 anti-sense assay
To investigate the effect of GATA3 on MUC1 gene expres­
sion, a GATA3 knock-down assay was performed with spe­
cific anti-sense oligonucleotides in MCF7 and T47D breast 
cancer cell lines. Cells were treated with optimal concentra­
tions of GATA3 anti-sense oligonucleotides (3 pg/ml) and 
examined 48 and 72 hours after transfection. Immunoblotting 
analyses of the cells treated with MCF7 and T47D showed 
that GATA3 translation was blocked by the anti-sense oligo­
nucleotide at both time points analyzed (namely at 48 and 72 
hours after transfection; Figure 7a). Treated cells showed a 
significant decrease in MUC1 expression (Figure 7). Total pro­
tein staining showed that these results were not due to differ­
ences in protein loading. The same result was obtained in a 
separate experiment with a MCF7-cell ELISA assay with a dif­
ferent monoclonal antibody (HMFG1) against MUC1 (Figure 
7b).
Discussion
Transcriptome profile analyses demonstrated that GATA3 
expression is strongly correlated with ERa status in breast 
cancer [3-9]. Recently we performed a cross-platform com­
parison between SAGE and DNA microarray profiles showing 
that the ESR1, GATA3, and MUC1 genes are very tightly co­
expressed in breast carcinomas (Figure 1) [3]. To validate the 
relationship of GATA3 and MUC1 in breast tissues further, we 
performed mRNA expression analyses of 36 invasive breast 
carcinomas by real-time RT-PCR, and protein expression anal­
ysis in 263 breast tissue samples by means of immunohisto­
chemistry on TMAs. Both analyses showed a statistical 
positive correlation between GA TA3 and MUC1 expression at 
the mRNA and protein levels (p < 0.01; Figures 2a and 3a). 
Interestingly, we also detected a positive correlation between 
GATA3 and MUC1 protein expression when both markers 
were evaluated in normal breast tissue as well (p = 0.001).
Two recent studies from gastrointestinal epithelial cells indi­
cated that GATA family members (GATA4 and GATA5) may 
have pivotal roles in the transcriptional upregulation of three 
mucin genes: MUC2, MUC3, and MUC4 [14,15]. These data 
led us to infer that GATA3 might have a role in the transcrip­
tional upregulation of MUC1 in breast epithelium.
To determine whether GATA3 protein was actively bound to 
the predicted consensus MUC1 promoter sequence (at -
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Figure 4
GATA-3 GATA-1 TSS
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GATA like GATAJike 200bp
-2ÉS1 TTGTTI^ CIAAGOCAGTGCAACTGCTTATTrTAGGGATTTTCCGOÄTjMKGTGGGGAAGTG&ÄAÖGAÄTCGGCGA  GT
-2571 AAGAOAAGCCTQGGAGGGTGGAAGTTAGGGATCTAGQGGAAGTTTGGCTGATTTGGGGATGCGGGrGGGGGAQGTGCTG
-2491 GATGQIGTTAAGTGAAÍ3GAT1GGGTGCCTCAGG®.GGAIGCCCGAAGT cctcccagaoccactt act cacggt ggcagcg
-2411 GCGAQLCTCCAGICTATCAAKÎATCCGCCGGGATGGAGAGCa^GGAGGCGGGGGCTGŒCCTGAGGrAGCGGGGAGGŒG
-2331 GGGGGCCGGGGGGCGGACGGGÄCGAGTGCAATATTGGCGGGGGAAAAAACAACACTGCACCGCGTOCCGTCCCTCCCGCC
-2251 CGCCCGGGCCCGÍSVTCCCGCTCCCCACCGCCTGAAGCCGGCCCGACCCGtAACCCGGGCCGCTGGGGAGTrGGGrTCACC
-2171 TTGGJCGCCAGA(ÄGACTTGGCGCCCGGAAGCAÄAGG&ATGGCAAGGGGGAGGGGG(ÄGG<ÄGAACGGQkGTTrGCGGA
-2Û91 GTCCAGAAGGCCQCTTTCCGÄCGCCCGGGCGTTGCGCGCGCTTGCTCTTTAAGTACT CAGACI GCGCGGCGCGAGCCGTC
-2011 CGCAIUGTffiCGCGTGTCCCAGCAACCGAÄCTGÄATGGCTGTTGCTTGGCaATGCCGGGAGTTGAGGTTTGGGGCCGCCC
-1931 KCTAGCTÄCTCGrGTTrrCTCCGGCCTGCGAGTrGGGGGGCTCCCGCCTCCCOGGCCCGCTCCTGGGCGCGCTGACGTC
-1051 ÄGATGrCCCCACCCCGCCCAQCGCCTGCCCCAAGGGTCTCGCCGCÄCACÄAAGCrCGGCCTCGGGCGCCGGCGCGCGGGC
-1771 GAGAGCGGTGGTCrCTCGCCTCCTGATCTQLTGCGCTCCAAZCCCCTGCCTCGCCGAAGTGTTTTIAAAGrGTTCTTIÜC
-1691 AACCTGTGTCTTTGGGGCTGAGAACTCTTTrCTGÄATACAGGCGGAACTGCTTCCGTCEGCCTAGAGGCÄCGCTGCGACT
-1611 GCGGtaCCCMGTrCCACGTGCTGCCGCGGCCTGQCaiÄCCTTCCTCCCCrCGTGCACrGCTGCCGCACÄCACCTCTTGG
-1531 CTGTCGCGCÄTTACGCACCTCACGTGTGCTm-GCCCCCCGCTÄCGTGCCTACCTGTCCCCAATAiXACIUTGCTCCCCA
-1451
-1371 CTTTGCTCTXrTC(XCCAGGCTGGAGTGCAATGGCCCGATCTCGGCTCAC7TGCAACCTCCGCCTCCaMGTTCAAGCGATT
-1291 CTCCTGCCTCAGŒTCCTGAGrAGCTGGGGrTAŒGCGCCCGCCACCACGCTCGGCTAATTTrTGTAGTTTTTAGTAGM;
-1211 ACGAGGTTTCACa.TCTrGGCCAGGCTGGTCTT®ACCCCTGÌCCTTGT  ®TCŒ1CTCGCCTCGGCCTTCCAAAGTGTTG
-1131 GGATTACGGGCGTGACGACCGTGCCÄCGCAICTGCCTCrTAAGTACÄTAACGGCCCAaiCAGAACGrGTCCAACTCCCCC
-1051 GCCCMTCTTCCAACGTCCTCTCCCACATÄCCTCGCTGCCCCTTCCACATÄCCTCTGGACCCCACCOGCTTÄGCTCCATTT
-971 CCTCCAGACGCCÄCCACCACQCGTCCCGGAGTGCCCCCrCCIAAAGCTCCCAGCCGTCCACCaTGCrGTGCGTTCCTCCC
-091 TCCCTGGCCÄCGGCAGTGACCCTTCTCTCCCGGGCCCTGCTTCCCTCTCGCGGGCTCTGCTGCCTCACTTAGGCAGCGCT
-811 GCCCTTACTCCTCrCCGCCCGGTCCGAGCGGCCCCTCAGCTTCGGCGCCCAGCCCCGCAAGGCTCOCGGTGACCACTAGA
-731
-651
-571
-491
GGGCGGGAGGAGCTCCTGGCCAGTGCrrGGAGAGTGGCAAGGAAGGACCCTAGGGTTCATCG&GCCCAGGTTTACTCCCT
_________ Sp1
TAAGTGGÄÄATrrCTrCCCCCÄCTCCTCCTrGGCrrrCTCCAAGGÄ3GGAACC€AGGCrGCTGGAAAGTCCGGCrGGGGC
STATIH -------
QSGfi&^TGTGGGTTCAGGGGAGAACQGGGTGTGGAACGGGACJLGGGAGCGGTT^AAGGGTGGGGCrATTCCGQGAAGTG
GIGGGGGGAÍ^^AGCCaiAAACTAGCACCDLGT^ACTCATOLTCCAGCCCTCTTATTrCTCGGCCGCTCrGCTTCAGTG
-411 GACCCGGGQLGGGCGGGGAAGTGGAGTGGGAGACCTAGGGGTGGGCrTCCCGACCTTGCTGTÄCAGGACCrCGÄCCTÄGC
-331 TGGCTTTGTTCCCCATCCCCACGTTRGTTGTTGCCCTGAGGCTAAAACTAGAGCCCAGGGGCCCCAAGTTCCAGACTGCC
-251
-171
-91
-11
CCTCCCCCCTCCOCCGGAGCCAGGGAGTGGrTGGTGAAAGGGGGAQGCCAGCTGGAGAACAAACGQGTAGrCAQGGGGTT
Spi
CTLGCSm-AGAGCCCITGTACCCTACCCAGGAATGGTTGGGGAGGAGGAGGAASLGGTAGGAGGTAGGGfflGGGGGCGGG
E41UC1 ,------------, -------------------
CTTTTGTCACCTGrCACCTGCTCGCrGTGCCTAGGGCGGGCGGGCQGGGAGTGGGGGGACCGGTAIAAAGCGGIAGGCGC 
CTGTGCCCGCTCCACCTCTCAJ!£CAGCCAGCGCCrGCCrGAATCTGTTCTGCCCCCTCCCCJ£CCATTTCACCACCACCArG
TSS ORF
MUC1 promoter sequence, (a) GATA c/s-elements map identified in MUC1 promoter region, (b) DNA sequence showing the TATA box (white box), 
the transcriptional start site +1 (TSS arrow) and the open reading frame (ORF arrow). Gray boxes indicate putative binding sites for GATA transcrip­
tion factors showing the following: a GATA1 sequence (-448), a GATA3 sequence (-2395) and four GATA-like sequences (-1446, -1574, -2472, 
and -2604). Known regulatory elements are underlined (Sp1, STAT1 /3, E-MUC1).
2398/-2393 from the transcriptional start site (TSS)) in vivo 
and in vitro, we performed ChIP and gel shift analyses in 
breast cancer cells. The ChIP assay in MCF7 demonstrated 
the existence of a functional GATA3 binding site within the 
MUC1 promoter (Figure 5). The EMSA studies further vali­
dated ChIP data (Figure 6). Having found that GATA3 tran­
scription factor efficiently recognizes a sequence motif in the 
distal portion of the MUC1 promoter, we proceeded to ana­
lyze the effects of GATA3 suppression on MUC1 protein 
expression in transiently transfected MCF7 cells. GATA3 
knockdown assays led to a significant decrease in MUC1 pro­
tein expression in MCF7 breast cancer cells (Figure 7), 
strongly suggesting an involvement of GATA3 in the modula­
tion of MUC1 expression.
The MUC1 promoter sequence has been analyzed previously 
for its ability to direct the expression of a reporter gene [19- 
21]. The construct (including 2.9 kb of MUC1 5'-flanking 
region) showed high expression levels in ZR75 cells but sur­
prisingly low levels in MCF7 and T47D cell lines. This study 
showed that tissue-specific expression of a reporter gene 
could be obtained with only 743 bp of 5' sequences of the 
MUC1 gene, using the ZR75 cell line [19]. However, the bind­
ing of GATA3 to the promoter regions of target genes gener-
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Figure 5 Figure 6
* 24? bp
Chromatin immunoprecipitation assay of GATA3 in MCF7 breast can­
cer cells. Chromatin complexes were crosslinked in vivo with formalde­
hyde (see the Materials and methods section). The GATA3-associated 
DNA fragments were immunoprecipitated (IP) with mouse monoclonal 
antibody against GATA3 (HG3-31). DNA samples were isolated before 
IP (lane labeled 'input'), after elution the unbound proteins from the Pro­
tein A-Sepharose batch (lane labeled 'eluted') and after specific IP 
(lane labeled 'ChiP', for chromatin immunoprecipitation), (a-c) PCR 
was performed with (a) flanking primers amplifying a GATA1 binding 
site on the MUC1 promoter (1 86 bp; see Figure 2), (b) flanking primers 
for amplification of exonic sequences of the HLA-DQA1 gene (242 bp; 
negative control), and (c) flanking primers for amplification of the 
GATA3-binding site on the MUC1 promoter (292 bp) as shown in Fig­
ure 2. (d-e) Second ChIP (reChIP) assay using the first eluted DNA- 
protein complex as input sample, (f) Western blot analysis of GATA3 
protein expression: a sample of MCF7 protein extract was run on a 
10°/o SDS-PAGE gel and assayed for GATA3 expression with the mon­
oclonal antibody used in ChIP assays (HG3-31). The expected wild­
type band of 48 kDa was immunodetected. Lane WM shows an SDS- 
7B prestained SDS-molecular mass standard (Sigma-Aldrich).
ate an open chromatin configuration that increases the 
accessibility to other main transcriptional regulators (perhaps 
STAT) in the vicinity of the TSS [30,31]. These data, together 
with the fact that GATA3 knock-down expression did not 
immediately abolish MUC1 expression, suggest that GATA3 
is partly required to drive MUC1 expression. The finding that 
GATA3 and MUC1 expression were correlated in SAGE, real­
time RT-PCR and TMA immunohistochemistry analyses shows 
statistical significance. It is also apparently a set of breast car­
cinomas in which there was no direct correlation between lev­
els of GATA3 and MUC1 expression. This suggests that 
GATA3 may contribute to MUC1 upregulation in a subset of 
breast cancer cells (namely ERa-positive breast carcinoma).
The role of GATA3 as a transcriptional upregulator of MUC1 
could be directly via a c/s-acting interaction and/or indirectly
<b)
MUC1-wt
(-) (+) GAT A3 mAb
4Super shift
♦ Complex
Electrophoretic mobility-shift assay employing cell nuclear extract from 
MCF7. (a) Gel shift analyses were performed with double-stranded oli­
gonucleotides (27 bp) as indicated: positive control probe containing 
the GATA3-binding element (GATA3-wt), a mimetic wild-type MUC1 
probe containing the predictive GATA3-binding site (MUC1-wt), and a 
probe sequence with predictive GATA3-binding site mutations (MUC1- 
mut). (b) The presence of GATA3 was confirmed by supershift assay. 
Nuclear extract prepared from MCF7 cells was preincubated with 
GATA3 antibody, and then incubated with the mimetic wild-type MUC1 
probe containing the GATA3-binding site (MUC1 -wt). Arrows to the 
right indicate the position of the free probe (FP), the probe-nuclear- 
protein complex (Complex), and the specifically retarded protein- 
GATA3-antibody-probe complex (Supershift).
via cross-talk between GATA3 and MUC1 co-activators such 
as ERa/SP1, STAT or FOG (friend-of-GATA cofactors). The 
transcriptional regulatory event, operating after the binding of 
GATA3 to the MUC1 promoter, remains to be determined. 
The MUC1 promoter contains several c/s-elements specific 
for transcription in lymphoid cells such as STAT, MZF1, XBP1, 
MYB and GATA [21]. The involvement of GATA and STAT 
proteins in cytokine signaling is well documented in the hemat­
opoietic and lymphoid systems [30]. Interestingly, a GATA- 
STAT synergy has been recently suggested as a general event 
that could account for cell-specific effects of transcriptional 
regulation [31]. The presence of these elements, which can 
upmodulate gene expression in lymphoid cells, are in accord 
with the observation that the MUC1 gene is expressed in acti­
vated T cells [32].
Alternatively, several putative estrogen and progesterone 
response elements (ERE/PRE) have been identified in the 
human MUC1 promoter by sequence analysis [33]. Zhou and 
colleagues [34] demonstrated that ER does not directly regu­
late the Muc1 promoter sequence in mice. It is possible that 
the MUC1 gene is transcriptionally regulated by non-ERE- 
mediated mechanisms, for example those involving ERa bind­
ing to a co-activator such as AP1 or SP1 [35]. It is interesting 
to note that two SP1 -binding sites have been characterized as 
important MUC1 transcriptional activators in epithelial cells 
[19,20]. Moreover, there are studies demonstrating protein-
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Figure 7
(a> T47DMCF7
GATA3 knock-down
— GATA3
— MUC1
----- Total 
protein
(b) GAT A3 control
(c>
GATA3
GATA3 knock-down analysis in MCF7 and T47D breast cancer cell 
lines, (a) Western blot analysis of GATA3 and MUC1 proteins in non­
treated (control) and GATA3 anti-sense treated cells (48 and 72 hours) 
in both breast cancer cell lines. SDS-PAGE silver protein staining 
showed equal amounts of total protein loaded, (b) MCF7 immunocyto­
chemistry of GATA3 anti-sense transfected cells showing no immuno­
reactivity to the anti-GATA3 antibody, and matching control cells show 
GATA3-positive nuclear localization, (c) Quantification of MUC1 pro­
tein expression by MCF7 culture ELISA assay. GATA3 anti-sense 
treated cells (48 hours) showed a statistically significant decrease in 
MUC1 expression compared with matched control cells (p = 0.001). 
Each experiment was performed in triplicate.
protein interaction between ERa and GATA1 in erythroid cells 
[36,37]. ERa binds to the GATA1 protein at two sites, one of 
which is a zinc-finger domain that is highly conserved among 
GATA family members [36].
Therefore, a possible way of explaining ESR1, GATA3, and 
MUC1 co-expression could very probably involve the forma­
tion of a complex between the ERa and GATA3 proteins that 
results in the upmodulation of MUC1 gene expression.
It has been shown that high expression of GATA3 correlates 
with low tumor grade by in silico analysis of cDNA microarray 
data [1 2]. As is known, tumor grade is a good measure of 
breast cancer progression and differentiation status. In this 
study we have demonstrated a strong correlation between 
loss of GATA3 protein expression and more advanced stages 
of breast cancer progression; that is, high-grade less differen­
tiated breast carcinomas expressed lower levels of GATA3 
protein on the basis of immunohistochemical studies (p = 
0.004). Similarly, Mehra and colleagues [38] showed that loss 
of GATA3 expression is associated with higher histological 
grade.
Our data agree with previously reported studies showing the 
role of GATA family members in the development and mainte­
nance of a more differentiated state. Interestingly, there is 
emerging evidence that membrane-associated mucins (MUC1 
and MUC4) contribute to the regulation of differentiation, mor­
phogenesis, and proliferation of breast epithelial cells [1 7,39]. 
Recent data show that a fragment of the MUC1 cytoplasmic 
tail can be translocated to the nucleus, driving the transcrip­
tional co-activator status of [3-catenin [40]. This finding sus­
tains the possibility that GATA3 might influence cell 
differentiation possibly through processes involving the upreg­
ulation of MUC1 gene expression.
Conclusion
Our findings suggest that GATA3 could contribute to the tran­
scriptional upregulation of MUC1 gene expression in some 
breast carcinomas.
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